Shanghai China, January 29,2026, Shanghai CirCode Biomed Co., Ltd. (CirCode), a leading clinical stage circular RNA biopharmaceutical company, announced that its leading pipeline, HM2002, the world...
SHANGHAI,China, December 17, 2025, Shanghai CirCode Biomed Co., Ltd. (CirCode) announced today that its proprietary circular RNA (circRNA) therapeutic, HM2002 Injection,has received its third Inves...
Shanghai,China, October 24, 2025, Shanghai CirCode Biomed Co., Ltd. announced that its innovativecircular RNA therapeutic, HM2003 injection(Hereinafterreferred to as HM2003), has been grantedOrphan...
Shanghai CirCode Biomed Co. Ltd. (CirCode), recently announced that its leading pipeline HM2002 received Investigational New Drug (IND)clearance from the US Food and Drug Administration (FDA)
Shanghai, China, January 10, 2025, Circode Biomed today announced that its leading pipeline HM2002 injection has received Investigational New Drug (IND) Approval from the National Medical Products...
On September 24, 2024, the patient was transferred to a general ward and is receiving level II nursing care. Vital signs and all clinical indicators remain stable.
SHANGHAI, China, August 14, 2024 – CirCode Biomed, an innovative biotechnology company focusing on the development of Circular RNA therapeutics, today announced the first-in-human investigator init...
Shanghai, China – CirCode Biomed announced today a feasibility study agreement with Bristol Myers Squibb to explore a potential therapeutic application of CirCode’s Circular RNA technology. The c...